Catherine Levitt - Astellas Pharma G Counsel

All Insiders . USA . 
Stock . Astellas Pharma . Stakeholders . Insider . Catherine Levitt
ALPMF Stock  USD 10.37  0.12  1.17%   

Insider

Catherine Levitt is G Counsel of Astellas Pharma
Phone81 3 3244 3000
Webhttps://www.astellas.com

Astellas Pharma Management Efficiency

The company has return on total asset (ROA) of 0.0653 % which means that it generated a profit of $0.0653 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0898 %, meaning that it generated $0.0898 on every $100 dollars invested by stockholders. Astellas Pharma's management efficiency ratios could be used to measure how well Astellas Pharma manages its routine affairs as well as how well it operates its assets and liabilities.
Astellas Pharma has accumulated 4.87 B in total debt with debt to equity ratio (D/E) of 0.0, which may suggest the company is not taking enough advantage from borrowing. Astellas Pharma has a current ratio of 1.31, which is within standard range for the sector. Debt can assist Astellas Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Astellas Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Astellas Pharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Astellas to invest in growth at high rates of return. When we think about Astellas Pharma's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Nadim AhmedBristol Myers Squibb
51
Karen HaleNovartis AG ADR
56
Samir MDNovartis AG ADR
62
Charlotte WieserNovartis AG ADR
N/A
Timothy PowerBristol Myers Squibb
N/A
Josep CatllaSanofi ADR
N/A
Bruno MnardSanofi ADR
N/A
Josephine FubaraSanofi ADR
N/A
Cari GallmanBristol Myers Squibb
N/A
Eva SchaeferJansenSanofi ADR
N/A
Gonzalo VinaAstraZeneca PLC ADR
N/A
MBA DVMAstraZeneca PLC ADR
65
Robert PharmDNovartis AG ADR
56
Michael QuigleyGilead Sciences
N/A
Paul HudsonSanofi ADR
57
Paula PriceBristol Myers Squibb
59
Paul PenepentNovartis AG ADR
N/A
Dante BeccariaSanofi ADR
N/A
Diane WilfongGilead Sciences
62
Aradhana MDAstraZeneca PLC ADR
50
Laurent GilhodesSanofi ADR
N/A
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan. ASTELLAS PHARMA operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 14522 people. Astellas Pharma [ALPMF] is a Pink Sheet which is traded between brokers over the counter.

Management Performance

Return On Equity0.0898
Return On Asset0.0653

Astellas Pharma Leadership Team

Elected by the shareholders, the Astellas Pharma's board of directors comprises two types of representatives: Astellas Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Astellas. The board's role is to monitor Astellas Pharma's management team and ensure that shareholders' interests are well served. Astellas Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Astellas Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
Minoru Kikuoka, CFO Officer
Naoki BSc, Chief VP
Kenji Yasukawa, Senior Executive Officer, Manager of Vaccine Business Promotion Office
Stig Ogata, VP Communications
Chihiro Yokota, Executive Officer, Director of Licensing and Alliance
Katsuyoshi Sugita, Chief Officer
Yoshitsugu Shitaka, Executive Officer and Presidentident of Subsidiary
Nobue Yasuda, Gen Department
Collette Taylor, VP HR
Catherine Levitt, G Counsel

Astellas Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Astellas Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity0.0898
Return On Asset0.0653
Profit Margin0.09 %
Operating Margin0.17 %
Current Valuation26.19 B
Shares Outstanding1.83 B
Shares Owned By Insiders0.37 %
Shares Owned By Institutions50.43 %
Price To Earning25.09 X
Price To Book2.38 X

Currently Active Assets on Macroaxis

CCitigroup
GMGeneral Motors
FFord Motor
GMGeneral Motors
VVisa Class A

Other Information on Investing in Astellas Pink Sheet

Astellas Pharma financial ratios help investors to determine whether Astellas Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Astellas with respect to the benefits of owning Astellas Pharma security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY